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Abstract 
The incidence of malaria in Indonesia is about two million cases annually. Dihydroartemisinin-piperaquine (DHP) is 
the first line therapy recommended for uncomplicated malaria treatment, whereas  DHP is still fully imported. The 
generic DHP tablet formulation has the potential to become the first of DHP drug which is locally produced. This 
study is aimed to formulate generic DHP film coated tablets for antimalaria drug. Tablets were compressed with the 
combination of wet granulation for piperaquine phosphate (PQP) and direct compression method for DHA and 
coated with a moisture barier coating material. The parameters to evaluate the quality of DHP tablets are physical 
properties, assay, and dissolution test. DHA and PQP assay were performed by HPLC method. The dissolution 
testing was conducted by in house method using HCl 0.1 N medium. The result shows physical properties of film-
coated tablets meet the requirement, i.e. uniform weight, 7.0-8.5 kp hardness, 0.02% friability and 3 minute 22 
seconds disintegration. The assay to determine  DHA in tablet was 95.17% and PQP was 97.05%. The result of 
dissolution testing shows the content of DHA and PQP in the tablet were 113.51% and 96.55%, respesctively. The 
formulation which is developed meets the general requirement of API in tablet 90–110% and dissolution 
requirement >75%.  
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Abstrak 
Kejadian malaria di Indonesia masih sangat tinggi, yaitu sekitar dua juta kasus per tahun. Dihidroartemisinin-
Piperakuin (DHP) merupakan terapi lini pertama untuk malaria, namun hingga saat ini sediaan yang ada masih 
merupakan obat impor. Formulasi tablet DHP generik ini berpotensi menjadi obat DHP pertama yang merupakan 
produksi dalam negeri. Penelitian ini bertujuan untuk menghasilkan formula tablet DHP generik salut selaput untuk 
obat antimalaria. Tablet dicetak dengan kombinasi dua metode, yaitu granulasi basah untuk piperakuin fosfat 
(PQP), dan cetak langsung untuk DHA, kemudian disalut untuk melindungi dari pengaruh kelembaban. Kualitas 
tablet diukur meliputi pemeriksaan fisik, penetapan kadar, dan uji disolusi. Penetapan kadar DHA dan PQP 
dilakukan menggunakan sistem Kromatografi Cair Kinerja Tinggi (KCKT). Uji disolusi dilakukan dengan metode in 
house menggunakan medium HCl 0.1 N. Hasil analisis menunjukkan bahwa tablet hasil formulasi memenuhi 
seluruh persyaratan fisik, yang terdiri dari memiliki keseragaman bobot, kekerasan 7.0-8.5 kP, keregasan 0.02%, 
dan waktu hancur 3 menit 22 detik. Penetapan kadar menunjukkan bahwa kandungan zat aktif dalam tablet hasil 
formulasi adalah  95.17% untuk DHA dan 97.05% untuk PQP. Sementara itu, dari hasil uji disolusi diperoleh 
kandungan DHA dan PQP dalam tablet masing-masing adalah 113.51% dan 96.55%, yang berarti memenuhi 
persyaratan umum kandungan zat aktif dalam tablet 90–110% dan persyaratan disolusi >75%. 
Kata kunci: Dihidroartemisinin; Piperakuin; Tablet; Salut selaput 
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INTRODUCTION 
Malaria is the most important parasite-
infection in human that can be treated by 
antimalarial drugs. Malarial cases are spread 
through WHO member countries. Eighty 
eight percent of global malarial cases was 
found in African region countries, followed 
by 10% in South East Asian region. 
Globally, 214 million people in 2015 were at 
risk of malarial infection, 438 thousand 
resulted in death. Global commitment in 
eliminating malaria successfully reduce 
malarial incidence and death by 37 and 60 
percent, respectively, in year 2000 through 
2015.
1
 
In Indonesia, malaria is still one of the 
diseases with the highest incidence. The 
biggest burden of the disease is in eastern 
provinces of Indonesia, where malaria is 
endemic. Indonesian climate is perfect for 
mosquito breeding. The decline in malaria 
cases and deaths were also reported in 
Indonesia. Indonesian national malaria 
prevalence decreases from 10.6% in 2010 to 
6% in 2013.
2,3
 Between the years 2000 to 
2013, Indonesia reported a decrease in 
malarial incidence of 5.34% per year and a 
reduction in malaria deaths of 5.19% per 
year.
4
 Although malaria cases and deaths in 
Indonesia has been declining, there are still 
problems encountered in achieving malaria 
elimination in 2030. Java and Bali has 
achieved the status of pre-elimination and 
elimination, while other areas is still 
considered as malarial endemic areas. 
Indonesia has 497 districts, and 54% of it is 
still categorized as an endemic districts.
5
 
Malaria cases occurred in all age groups and 
the highest is reported in the age group of 
≥15 years. Thirty three percents of malaria 
patients were treated by Artemisinin-based 
Combination Therapy (ACT), and only 
14.46% received ACT within the first 24 
hours of fever and took the medication for 3 
(three) days.
3
 
Artemisinin-based Combination Therapy 
(ACT) currently is the best antimalarial 
medication.
6
 Fixed-dose combinations 
(FDC) of 40 mg dihidroartemisinin (DHA) 
and 320 mg of piperaquine phosphate (PQP) 
is recommended by the program bearer since 
2008 and is widely used in Indonesia since 
2011.
7, 8
 DHP clinical trials against cases of 
falciparum and vivax malaria without 
complications, compared to artesunate-
amodiaquine (AS-AQ) and artemether-
lumefantrine (AL), showed that  DHP has 
better response (recovery >95%) and mild 
side effects.
9,10
 In addition, DHP 
combination is safe, more effective, and 
cheaper than other ACT.
11,12
 Therefore, DHP 
tablet is currently listed as antimalarial drug 
by the national drug formulary.
13
 The high 
incidence of malaria in Indonesia resulted in 
high demand of antimalarial drug. However, 
the real problem is the availability of the 
drug,whereas  DHP is still fully imported. 
This is the main reason for Indonesian 
government to formulate and produced DHP 
locally.  
Dihydroartemisinin (DHA) is an unstable 
active ingredient, easily oxidized and 
hygroscopic. Film-coating is used to protect 
the active substances contained in tablets 
from moisture. This study aims to formulate 
generic DHP film coated tablet as 
antimalarial drugs to be produced locally in 
Indonesia. 
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METHOD 
Design of this study is a laboratory-
based experimental research. The study was 
conducted in March to December 2015 in 
Pharmacy laboratory in Center for 
Biomedical and Basic Technology of Health 
andResearch and Development laboratory in 
PT Indofarma, Tbk. Ethical clearance for 
this research has been granted from Health 
Research Ethic Committee, NIHRD, No: 
LB.02.01/5.2/KE.286/2015. Activities 
performed in this research include core 
tablet compression, tablet coating, tablet 
physical analysis, tablet assay, and 
dissolution study. 
Core tablet 
Core DHP tablet was constructed using 
wet granulation method. Kollidon solution 
was prepared by dissolving Kollidon K30 in 
aquadest. Piperaquine starch 1500, LHCP 
LH 21 were added into the super mixer, 
followed by Kollidon solution and mixed 
throughly, and then sieved using mesh 20 
sieve. Drying was performed using oven. 
Dried granule, together with DHA, talc, and 
magnesium stearate were added into cone 
mixer to be homogenized. This granule mass 
was compressed using tablet compression 
machine, weighing 494 mg, using round 
convex punches, with 12 mm diameter. 
Tablet coating 
Core tablets were placed inside a coating 
pan. Warm air were blown through a 
blower, followed by coating material 
suspension. Opadry AMB suspension in 
water was used as a coating material with 
weight gain targeted at 5%. 
Tablet physical analysis 
The physical analysis of the tablet were 
conducted on core and film-coated tablet. 
Quality testing performed included tablet 
appearance, weight uniformity, hardness, 
thickness, friability, and disintegration 
time.
14
  
Assay 
DHP tablet assay was performed by 
High Performance Liquid Cromatography 
(HPLC) instrument (Waters). Twenty DHP 
tablets were weighed, crushed, and mixed. 
For active pharmaceutical ingredient (API) 
assay, sufficient amount of samples equal to 
25 mg DHA and 10 mg PQP were taken. 
Assays for DHA and PQP were conducted 
separately. DHA sample was put in 
volumetric flask and then dilluted with 60% 
acetonitrile (ACN) to 25 mL. HPLC method 
applied for DHA analysis was as follow: 
Trifluoroacetic acid 0.1%-ACN (40-60) 
adjust pH to 3.0 by adding dilluted 
ammonium; 1.0 mL/min flow; 20 µL 
injection volume, and UV detection at 216 
nm. PQP samples were dilluted with 40% 
ACN in 50 mL volumetric flask. This 
sample was analysed using HPLC with 
phosphar buffer pH 7.0-CAN (60:40) as the 
eluent; flow rate 1.0 mL/min; 20 µL 
injection volume; and UV detection at 320 
nm. 
API content was calculated using the 
formula as follows: 
        ( )  
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Ru : main peak area of test substance 
Rs : main peak area of standard reference 
Ws : weight of API in standard solution  
W : weight of API in sample solution 
f : standard equivalence factor 
g : API content in each tablet 
 
Comparative dissolution testing 
DHP tablet dissolution testing was 
peformed using  type II dissolution tester 
(Hanson Vision G2 and AutoPlus®) at 100 
rpm of speed, using 900 mL HCl 0.1 N as 
the medium. Dissolution filtrates were taken 
at minutes 10, 15, and 30, and it must be at 1 
cm from tube wall. Dissolution medium was 
immediately added at the same volume with 
filtrate taken to maintain the sink condition. 
The filtrate was then analyzed using 
spectrophotometer. Each amount gained was 
plotted against time when the filtrate taken 
in order to see the dissolution profile. 
Furthermore the dissolution profile of 
sample DHP tablets was compared to DHP 
innovator tablet. 
DHA content in dissolution sample was 
done by measuring standard reference and 
test substance absorbance at (λ) 238 nm. The 
ingredientwas calculated by following 
formula: 
 
 
 
 
Au: absorbance of test substance 
As: absorbance of standard reference 
Ws: weight of DHA in standard solution, mg 
f   : standard equivalence factor 
 
PQP content in dissolution sample was 
done by measuring standard reference and 
test substance absorbance at (λ) 345 nm. The 
content was calculated utilizing following 
formula: 
 
 
 
Au : absorbance of test substance 
As : absorbance of standard reference 
Ws : weight of PQP in standard solution, mg  
f : standard equivalence factor 
 
RESULT AND DISCUSSION 
Physical quality, API content, and 
dissolution profile of DHP tablet samples 
were performed to evaluate  the quality of 
the tablets. Several parameters were done for 
physical quality, such as physical 
appearance, weight uniformity, thickness, 
hardness, friability, and disintegration time.  
Film-coated DHP tablet was made 
through two steps. Wet granulation for PQP 
was made as the first step. which aimed to 
improve the granules’ flowability. The 
second step was to add DHA and directly 
compress the mixture since DHA is unstable 
to temperature and humidity.
15
 Core tablet 
was then coated with a blue-coloured 
moisture barrier coating material to protect it 
from humidity. Tablet physical testing result 
is reported in Table 1. 
Tablet physical appearances comply with 
all the requirements. Round shape and blue 
colour was chosen to match the innovator 
product. Weight uniformity is a very 
important parameter in determining tablet 
quality, because it will affect the API 
content. For tablets weighing more than 200 
mg, no more than 2 tablets are allowed to 
deviate more than 5% from its mean weight. 
The result shows that the tablets meet the 
requirement. TIn addition, this  formula have 
a good flow ability which will produce 
tablets with uniform weight. 
 
                        Au x Ws x f x 0,5 
Content  (%)   = --------------------- x 100 % 
                              As x 40 
 
                        Au x Ws x f x 5 
Content  (%)   = ---------------------- x 100 % 
                              As x 320 
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Table 1. Tablet physical testing result 
Parameter  Requirement Test result 
Appearance 
Round shaped, convex,  
diameter 12 mm, blue coloured 
Round shaped, convex,  
diameter 12 mm, blue 
coloured 
Core tablet weight (mg) 494 ± 15 483 - 504 
Film-coated tablet weight 
(mg) 
510  ± 15 508 – 520 
Thickness (mm) 4,5 – 4,9 4,6 – 4,7 
Hardness (Kp) 7 – 10 7,0 – 8,5 
Friability (%)  < 0,3 0,02 
Disintegration time 
(minutes) 
< 30 2’12” – 3’22” 
 
The results of friability tablet test is 
0.02%. This is an excellent result since 
coating process require hard tablet. As stated 
in United State Pharmacopoeia, a good tablet 
must have friability not exceed than 1%. 
Less friability may minimize the risk of 
tablet damage because during coating 
process tablets should stand against friction 
and shock, either between tablet and coating 
pan or between the tablets itself.  
In addition, the friability test is also 
useful to predict the resistance of a tablet 
when subjected to mechanical stress or 
abrasion during the manufacturing process, 
packaging and transport. Friability parameter 
is important. When a tablet has high 
friability, larger amount of tablet will be lost 
during such process and the amount of the 
core substance would not be in accordance 
with the predetermined formula and would 
compromised the API dose when consumed. 
The low value of friability is due to the use 
of appropriate binder in the formulation so 
that the tablet mass became more compact 
and harder. 
Tablet hardness test was performed to 
illustrate the tablet resistance to pressure, 
shock, and erosion during the production 
process, packaging, transport or distribution. 
The tablets’ hardness value was 7.0 to 8.5 
Kp which is qualified as a good tablet. An 
ideal tablet should be hard enough but also 
should be arranged (not too hard) in order to 
comply with tablet disintegration and 
dissolution requirements. If the tablet is too 
hard, it will took longer time to be dissolved. 
Tablet that is too soft can not retain its shape 
in the next process such as coating, 
packaging, and delivery.
16,17
  
Tablet disintegration time describes the 
time required by the tablet to disintegrate in 
body fluids. The process of tablet 
disintegration is preceded by the absorption 
of water so that the tablet can be broken into 
parts. Film coated tablet was found to have 
disintegration time ranging from 2 minutes 
12 seconds to 3 minutes 22 seconds and 
meet the requirements of less than 30 
minutes for coated tablets. Disintegration 
time is a prerequisite for dissolution. 
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Table 2. Core and film-coated DHP tablet assay result 
Active ingredients 
% assay 
Requirement Core tablet Film-coated tablet 
DHA 90-110 98,11 95,17 
PQP 90-110 99,73 97,05 
 
The tablet will first destroyed, and then 
the active ingredients will be separated, 
dissolved, absorbed and distributed into the 
target site. Longer disintegration time will 
result in longer dissolution time so the onset 
of the drug will be delayed. Good tablet 
disintegration time is due to the excellent 
ability of tablet filler in absorbing water and 
expands. This was also enhanced with the 
addition of disintegrant that will counter the 
particle bond resulting in faster tablet 
disintegration time.
18, 19
   
Assay of the active substance in the 
tablet DHP was performed using in-house 
developed methods based on research by 
D'Acquarica since there is no official assay 
method for this tablet in reference books 
such as the Indonesian Pharmacopoeia, USP, 
and the British Pharmacopoeia. The assay 
results of core and film coated DHP tablet 
can be seen in Table 2. 
Based on the examination of active 
ingredient, the formulated DHP tablet 
formulation complied with the common 
requirements of active ingredient in the drug. 
This illustrates that the tablet formula and 
the granulation method is good enough to be 
developed into a commercial product 
because it produces products with eligible 
level of active ingredients. 
DHP tablet dissolution testing is 
conducted using in-house developed 
methods because there is no official method 
yet in reference books. The test was done on 
each sample with sampling times at minutes 
10, 15 and 30. The minimum level to be 
expected in minute 30 was 75%. 
Comparative dissolution test was conducted 
to determine the quality of drugs based on 
drug bioavailability predictions compared to 
the innovator drug. The dissolution 
properties of a drug directly related to its 
pharmacological activity since it is a 
prerequisite for the absorption of the drug 
and clinical response. The comparative 
dissolution test of generic DHP tablet 
compared with the results of DHP innovator 
tablet is shown in Figure 1.  
As reported in Figure 1, the dissolution 
profile of formulated DHP tablet was similar 
to the innovator tablet. Comparative 
dissolution test showed that in generic and 
innovator DHP tablet, both active 
ingredients has been dissolved more than 
70% in 10 minutes. At the end of testing 
time (30 minutes), it can be seen that the 
levels of the active substance released from 
the generic and innovator tablets DHP has 
met the requirements, which was more than 
75%. Tablet formulation, tablet mixing and 
compressing method, as well as excipients 
plays important role in creating tablet with 
good dissolution profile.
20,21 
The final 
properties of preparation, such as 
bioavailability and stability is very 
dependent on the selected excipient, the 
amount of excipient used, and its interaction 
with the active substance or other excipients. 
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Figure 1. Comparative dissolution test result between generic and innovator DHP tablet 
 
 
CONCLUSION 
Generic film-coated DHP tablet meets all the 
requirements, e.g physical quality, content 
uniformity, and dissolution. This formulated 
generic tablet is very prospective to be up 
scaled and developed into the first generic 
DHP tablet produced locally in Indonesia. 
 
SUGGESTION 
Further stability testing and bioequivalence 
study need to be performed on the generic 
DHP tablet. 
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